Stanislas Veillet

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Drug Candidate BIO101 for Spinal Muscular Atrophy as Monotherapy or Combined With the Antisense Oligonucleotide ASO-10-27.

Drug Candidate BIO101 for Spinal Muscular Atrophy as Monotherapy or Combined With the Antisense Oligonucleotide ASO-10-27.

Journal: Journal of cachexia, sarcopenia and muscle

Published: March 24, 2025

Modulation of the renin-angiotensin system against COVID-19: A path forward?

Modulation of the renin-angiotensin system against COVID-19: A path forward?

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: December 03, 2024

BIO101 in Sarcopenic Seniors at Risk of Mobility Disability: Results of a Double-Blind Randomised Interventional Phase 2b Trial.

BIO101 in Sarcopenic Seniors at Risk of Mobility Disability: Results of a Double-Blind Randomised Interventional Phase 2b Trial.

Journal: Journal of cachexia, sarcopenia and muscle

Published: May 28, 2024

Characterizing sarcopenia and sarcopenic obesity in patients aged 65 years and over, at risk of mobility disability: a multicenter observational trial (SARA-OBS).

Characterizing sarcopenia and sarcopenic obesity in patients aged 65 years and over, at risk of mobility disability: a multicenter observational trial (SARA-OBS).

Journal: BMC geriatrics

Published: March 28, 2024

RAR Inhibitors Display Photo-Protective and Anti-Inflammatory Effects in A2E Stimulated RPE Cells In Vitro through Non-Specific Modulation of PPAR or RXR Transactivation.

RAR Inhibitors Display Photo-Protective and Anti-Inflammatory Effects in A2E Stimulated RPE Cells In Vitro through Non-Specific Modulation of PPAR or RXR Transactivation.

Journal: International journal of molecular sciences

Published: December 20, 2023

Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial.

Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial.

Journal: EClinicalMedicine

Published: July 10, 2023

Anti-Inflammatory Effects and Photo- and Neuro-Protective Properties of BIO203, a New Amide Conjugate of Norbixin, in Development for the Treatment of Age-Related Macular Degeneration (AMD).

Anti-Inflammatory Effects and Photo- and Neuro-Protective Properties of BIO203, a New Amide Conjugate of Norbixin, in Development for the Treatment of Age-Related Macular Degeneration (AMD).

Journal: International journal of molecular sciences

Published: January 02, 2023

BIO101 stimulates myoblast differentiation and improves muscle function in adult and old mice.

BIO101 stimulates myoblast differentiation and improves muscle function in adult and old mice.

Journal: Journal of cachexia, sarcopenia and muscle

Published: November 16, 2022

A Phase 1 study for safety and pharmacokinetics of BIO101 (20-hydroxyecdysone) in healthy young and older adults.

A Phase 1 study for safety and pharmacokinetics of BIO101 (20-hydroxyecdysone) in healthy young and older adults.

Journal: Journal of cachexia, sarcopenia and muscle

Published: May 13, 2022

A comparison between virus- versus patients-centred therapeutic attempts to reduce COVID-19 mortality.

A comparison between virus- versus patients-centred therapeutic attempts to reduce COVID-19 mortality.

Journal: Emerging microbes & infections

Published: November 16, 2021

20-Hydroxyecdysone activates the protective arm of the RAAS via the MAS receptor.

20-Hydroxyecdysone activates the protective arm of the RAAS via the MAS receptor.

Journal: Journal of molecular endocrinology

Published: October 01, 2021

20-Hydroxyecdysone, from Plant Extracts to Clinical Use: Therapeutic Potential for the Treatment of Neuromuscular, Cardio-Metabolic and Respiratory Diseases.

20-Hydroxyecdysone, from Plant Extracts to Clinical Use: Therapeutic Potential for the Treatment of Neuromuscular, Cardio-Metabolic and Respiratory Diseases.

Journal: Biomedicines

Published: April 02, 2021

Showing 1-12 of 20

Last Updated: 09/26/2026